Boothbay Fund Management’s Kura Oncology KURA Stock Holding History

Boothbay Fund Management’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-45,656	Closed	-$1.01M	–	1136
2020 Q2	$744K	Sell	45,656 -40,193	-47%	-$580K	0.05%	462
2020 Q1	$854K	Buy	+85,849	New	+$983K	0.07%	337
2019 Q4	–	Sell	-33,685	Closed	-$511K	–	918
2019 Q3	$511K	Buy	+33,685	New	+$600K	0.05%	453

Other funds holding KURA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Boothbay Fund Management's KURA Position: Q3 2020 in Review

Boothbay Fund Management sold out of Kura Oncology (KURA) in Q3 2020, closing a stake of 45,656 shares — an estimated $1.01M sold.

Boothbay Fund Management first reported a position in KURA in Q3 2019 and held it in 3 quarters. The position peaked at $854K in Q1 2020. 162 funds tracked by Wall St. Rank hold KURA as of Q3 2020.

Boothbay Fund Management reported no remaining Kura Oncology position as of Q3 2020 after selling out during the quarter.
Boothbay Fund Management sold 45,656 Kura Oncology shares in Q3 2020, an estimated $1.01M.
Boothbay Fund Management first reported a position in Kura Oncology in Q3 2019 and held it in 3 quarters.
Boothbay Fund Management's Kura Oncology position peaked at $854K in Q1 2020.
162 funds tracked by Wall St. Rank held Kura Oncology as of Q3 2020.

Based on Boothbay Fund Management's 13F filing for Q3 2020, filed 16 Nov 2020.